Inhibitex has received fast track approval from the Food and Drug Administration for its proposed treatment of blood infections.

The drug, called Aurexis, is currently in Phase II clinical trials.
Fast track approval could lead to accelerated review or approval by the FDA for drugs that could treat serious or life-threatening illnesses.

The mortality rate for the infections is as high as 35 percent, according to Inhibitex.